A proposal for including assessment of tissue eosinophilic infiltration during pathological reporting of invasive mammary carcinoma with the incorporation of its significance regarding HER2-NEU status is hopefully advised, definitely after further large-scale prospective clinicopathological studies searching for any associated peripheral eosinophilia as well as tumor-infiltrating lymphocytes with a particular concern to the era of immune checkpoint inhibitors, an issue of most significant concern in modern oncology. This evidence concerns the gene ERBB2 and Increased total eosinophil count.